Literature DB >> 27774310

Translating Stem Cell Biology Into Drug Discovery.

Ilyas Singeç1, Anton Simeonov1.   

Abstract

Pluripotent stem cell research has made extraordinary progress over the last decade. The robustness of nuclear reprogramming of somatic cells into induced pluripotent stem cells (iPSCs) has created entirely novel opportunities for drug discovery and personalized regenerative medicine. Patient- and disease-specific iPSCs can be expanded indefinitely and differentiated into relevant cell types of different organ systems. As the utilization of iPSCs is becoming a key enabling technology across various scientific disciplines, there are still important challenges that need to be addressed. Here we review the current state and reflect on the issues that the stem cell and translational communities are facing in bringing iPSCs closer to clinical application.

Entities:  

Year:  2016        PMID: 27774310      PMCID: PMC5073788     

Source DB:  PubMed          Journal:  Drug Target Rev        ISSN: 2059-1349


  38 in total

Review 1.  Induced pluripotent stem cells--opportunities for disease modelling and drug discovery.

Authors:  Marica Grskovic; Ashkan Javaherian; Berta Strulovici; George Q Daley
Journal:  Nat Rev Drug Discov       Date:  2011-11-11       Impact factor: 84.694

Review 2.  Animal models of neuropsychiatric disorders.

Authors:  Eric J Nestler; Steven E Hyman
Journal:  Nat Neurosci       Date:  2010-09-27       Impact factor: 24.884

Review 3.  Drug development for CNS disorders: strategies for balancing risk and reducing attrition.

Authors:  Menelas N Pangalos; Lee E Schechter; Orest Hurko
Journal:  Nat Rev Drug Discov       Date:  2007-07       Impact factor: 84.694

4.  Neural progenitors from human embryonic stem cells.

Authors:  B E Reubinoff; P Itsykson; T Turetsky; M F Pera; E Reinhartz; A Itzik; T Ben-Hur
Journal:  Nat Biotechnol       Date:  2001-12       Impact factor: 54.908

5.  Can animal models of disease reliably inform human studies?

Authors:  H Bart van der Worp; David W Howells; Emily S Sena; Michelle J Porritt; Sarah Rewell; Victoria O'Collins; Malcolm R Macleod
Journal:  PLoS Med       Date:  2010-03-30       Impact factor: 11.069

6.  Embryonic stem cell lines derived from human blastocysts.

Authors:  J A Thomson; J Itskovitz-Eldor; S S Shapiro; M A Waknitz; J J Swiergiel; V S Marshall; J M Jones
Journal:  Science       Date:  1998-11-06       Impact factor: 47.728

7.  Genomic responses in mouse models poorly mimic human inflammatory diseases.

Authors:  Junhee Seok; H Shaw Warren; Alex G Cuenca; Michael N Mindrinos; Henry V Baker; Weihong Xu; Daniel R Richards; Grace P McDonald-Smith; Hong Gao; Laura Hennessy; Celeste C Finnerty; Cecilia M López; Shari Honari; Ernest E Moore; Joseph P Minei; Joseph Cuschieri; Paul E Bankey; Jeffrey L Johnson; Jason Sperry; Avery B Nathens; Timothy R Billiar; Michael A West; Marc G Jeschke; Matthew B Klein; Richard L Gamelli; Nicole S Gibran; Bernard H Brownstein; Carol Miller-Graziano; Steve E Calvano; Philip H Mason; J Perren Cobb; Laurence G Rahme; Stephen F Lowry; Ronald V Maier; Lyle L Moldawer; David N Herndon; Ronald W Davis; Wenzhong Xiao; Ronald G Tompkins
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-11       Impact factor: 11.205

8.  Regulatory networks define phenotypic classes of human stem cell lines.

Authors:  Franz-Josef Müller; Louise C Laurent; Dennis Kostka; Igor Ulitsky; Roy Williams; Christina Lu; In-Hyun Park; Mahendra S Rao; Ron Shamir; Philip H Schwartz; Nils O Schmidt; Jeanne F Loring
Journal:  Nature       Date:  2008-08-24       Impact factor: 49.962

Review 9.  The 3R principle: advancing clinical application of human pluripotent stem cells.

Authors:  Michael D O'Connor
Journal:  Stem Cell Res Ther       Date:  2013-03-08       Impact factor: 6.832

10.  Biological insights from 108 schizophrenia-associated genetic loci.

Authors: 
Journal:  Nature       Date:  2014-07-22       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.